{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000062","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.561238+00:00","generated_at":"2026-06-02T04:37:17.839967+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths","bullets":["Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.","Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.","Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.","Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000062","json":"https://secwatch.observer/filing/0000939767-24-000062.json","markdown":"https://secwatch.observer/filing/0000939767-24-000062.md","text":"https://secwatch.observer/filing/0000939767-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/0000939767-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/exel-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:37:17.839967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}